- Home
- MREO vs TEI Comparison
MREO vs TEI Comparison
Compare MREO & TEI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MREO
- TEI
- Stock Information
- Founded
- MREO 2015
- TEI 1993
- Country
- MREO United Kingdom
- TEI United States
- Employees
- MREO N/A
- TEI N/A
- Industry
- MREO Biotechnology: Pharmaceutical Preparations
- TEI Finance Companies
- Sector
- MREO Health Care
- TEI Finance
- Exchange
- MREO Nasdaq
- TEI Nasdaq
- Market Cap
- MREO 311.8M
- TEI 282.9M
- IPO Year
- MREO N/A
- TEI N/A
- Fundamental
- Price
- MREO $2.16
- TEI $6.23
- Analyst Decision
- MREO Strong Buy
- TEI
- Analyst Count
- MREO 5
- TEI 0
- Target Price
- MREO $7.40
- TEI N/A
- AVG Volume (30 Days)
- MREO 1.4M
- TEI 142.4K
- Earning Date
- MREO 11-11-2025
- TEI 01-01-0001
- Dividend Yield
- MREO N/A
- TEI 10.51%
- EPS Growth
- MREO N/A
- TEI N/A
- EPS
- MREO N/A
- TEI N/A
- Revenue
- MREO $500,000.00
- TEI N/A
- Revenue This Year
- MREO N/A
- TEI N/A
- Revenue Next Year
- MREO $72.16
- TEI N/A
- P/E Ratio
- MREO N/A
- TEI N/A
- Revenue Growth
- MREO N/A
- TEI N/A
- 52 Week Low
- MREO $1.47
- TEI $4.35
- 52 Week High
- MREO $4.72
- TEI $5.39
- Technical
- Relative Strength Index (RSI)
- MREO 61.75
- TEI 52.18
- Support Level
- MREO $1.94
- TEI $6.10
- Resistance Level
- MREO $2.28
- TEI $6.28
- Average True Range (ATR)
- MREO 0.12
- TEI 0.09
- MACD
- MREO 0.01
- TEI -0.01
- Stochastic Oscillator
- MREO 65.53
- TEI 42.46
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
About TEI Templeton Emerging Markets Income Fund Inc.
Templeton Emerging Markets Income Fund is a closed-end fund. It seeks high, current income, with a secondary goal of capital appreciation, by investing, under normal market conditions. The company's investment portfolio includes Foreign Government and Agency Securities; Quasi-Sovereign and Corporate Bonds; Common Stocks and Other Equity Interests, and Short-Term Investments, and Money Market Funds.